Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 1,220 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Revelation Biosciences Inc | REVB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.14 | 6.51% | 2.29 | 04:54:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.15 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 24 | 1,220 | - | 1.7801 - 39.30 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 04:53:42 | formt | 132 | $ 2.29 | USD |
Revelation Biosciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 4.2k | 209.91k | - | 0 | -120k | -0.57 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Revelation Biosciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical REVB Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.36 | 2.5199 | 1.7801 | 2.03 | 67,626 | -0.07 | -2.97% |
| 1 Month | 2.47 | 2.96 | 1.7801 | 2.45 | 68,430 | -0.18 | -7.29% |
| 3 Months | 12.20 | 25.26 | 1.7801 | 5.83 | 422,130 | -9.91 | -81.23% |
| 6 Months | 20.244 | 25.26 | 1.7801 | 8.00 | 273,829 | -17.95 | -88.69% |
| 1 Year | 35.10 | 39.30 | 1.7801 | 17.81 | 237,410 | -32.81 | -93.48% |
| 3 Years | 8,799.00 | 10,237.50 | 1.7801 | 982.33 | 1,290,279 | -8,796.71 | -99.97% |
| 5 Years | 8,799.00 | 10,237.50 | 1.7801 | 982.33 | 1,290,279 | -8,796.71 | -99.97% |
Revelation Biosciences Description
| Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. |
